相关实验视频
Updated: Jun 17, 2025
08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
21.0K
NKG2D双特异性增强NK和CD8+T细胞抗瘤免疫力
Aurelie Herault1, Judy Mak1, Josefa de la Cruz-Chuh2
1Department of Molecular Oncology, Genentech, South San Francisco, CA, USA.
Cancer immunology, immunotherapy : CII
|August 7, 2024
概括
用双特异性抗体向NKG2D受体可增强天然杀手 (NK) 和CD8+T细胞对固体瘤的反应. 这种方法有望增强现有的癌症免疫疗法,克服瘤免疫抑制.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 癌症免疫疗法通过基于T细胞和NK细胞的方法取得了重大进展.
- 固体瘤经常表现出免疫抑制机制,限制了抗瘤免疫细胞的活动.
- 需要新的策略来增强瘤微环境中的免疫细胞激活.
研究的目的:
- 研究向NKG2D共刺激受体以增强抗瘤免疫反应的潜力.
- 开发和评估NKG2D双特异性抗体,以增强T和NK细胞对HER2表达性乳腺癌的活性.
主要方法:
- 鉴定NKG2D为标,因为它在瘤透淋巴细胞 (TILs) 上表达.
- 开发出人类和小鼠替代NKG2D共刺激受体双特异性 (CRBs) 向HER2 (HER2-CRB).
- 评估了单独和与T细胞依赖双特异性抗体 (TDB) 结合的HER2-CRB的体外和体内疗效.
主要成果:
- 在体外,HER2-CRB增强了NK细胞的激活和细胞因子的产生.
- 组合疗法 (HER2-CRB + HER2-TDB) 改善了T细胞细胞毒性,细胞因子产生和体内抗瘤活性.
- 鼠HER2-CRB在体内提高了疗效,增强了NK和T细胞的反应,并促进了 CD8+ T细胞分化.
结论:
- 用双特异性抗体向NKG2D有效地增强NK和CD8+T细胞的抗瘤免疫反应.
- NKG2D-bispecifics为癌症免疫疗法提供了广泛的组合潜力,补充了正在进行的临床试验.
相关概念视频
01:27Cytotoxic T Cells-mediated Immune Response
861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861
01:27Tumor Immunotherapy
497
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
497
01:22T Cell Activation and Clonal Selection
693
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
693
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K